Lexicon Pharmaceuticals (NASDAQ:LXRX) Now Covered by StockNews.com

Equities researchers at StockNews.com began coverage on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report) in a research report issued to clients and investors on Sunday. The brokerage set a "sell" rating on the biopharmaceutical company's stock.

LXRX has been the subject of a number of other reports. HC Wainwright reissued a "buy" rating and issued a $4.00 price objective on shares of Lexicon Pharmaceuticals in a research note on Friday, March 28th. Leerink Partners reiterated a "market perform" rating and issued a $1.00 price target (down previously from $2.00) on shares of Lexicon Pharmaceuticals in a research note on Tuesday, March 4th. Piper Sandler lowered their price objective on Lexicon Pharmaceuticals from $10.00 to $6.00 and set an "overweight" rating on the stock in a research report on Friday, March 7th. Needham & Company LLC reaffirmed a "hold" rating on shares of Lexicon Pharmaceuticals in a research note on Monday, March 3rd. Finally, Leerink Partnrs downgraded Lexicon Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, March 5th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Hold" and an average price target of $3.67.

Lexicon Pharmaceuticals Stock Performance

NASDAQ LXRX traded up $0.01 on Friday, hitting $0.51. 365,671 shares of the company traded hands, compared to its average volume of 6,308,597. The business's 50 day moving average price is $0.51 and its 200-day moving average price is $0.89. Lexicon Pharmaceuticals has a 52-week low of $0.28 and a 52-week high of $2.45. The company has a current ratio of 7.45, a quick ratio of 7.43 and a debt-to-equity ratio of 0.56. The company has a market capitalization of $124.35 million, a price-to-earnings ratio of -0.68 and a beta of 1.02.

Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report) last posted its quarterly earnings data on Thursday, March 6th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, beating analysts' consensus estimates of ($0.11) by $0.02. The firm had revenue of $26.55 million for the quarter, compared to analysts' expectations of $6.48 million. Lexicon Pharmaceuticals had a negative return on equity of 107.38% and a negative net margin of 4,109.41%. Equities analysts expect that Lexicon Pharmaceuticals will post -0.66 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in LXRX. Charles Schwab Investment Management Inc. grew its holdings in Lexicon Pharmaceuticals by 4.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,417,295 shares of the biopharmaceutical company's stock valued at $2,225,000 after buying an additional 58,147 shares in the last quarter. BNP Paribas Financial Markets grew its holdings in shares of Lexicon Pharmaceuticals by 71.2% in the third quarter. BNP Paribas Financial Markets now owns 31,853 shares of the biopharmaceutical company's stock valued at $50,000 after purchasing an additional 13,246 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in Lexicon Pharmaceuticals in the third quarter worth $189,000. State Street Corp raised its stake in Lexicon Pharmaceuticals by 6.8% during the third quarter. State Street Corp now owns 2,471,215 shares of the biopharmaceutical company's stock valued at $3,880,000 after purchasing an additional 157,738 shares in the last quarter. Finally, XTX Topco Ltd bought a new position in Lexicon Pharmaceuticals during the third quarter valued at $126,000. Hedge funds and other institutional investors own 74.70% of the company's stock.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.